Psychemedics Company Insiders

PMD Stock  USD 2.65  0.06  2.32%   
Psychemedics employs about 116 people. The company is managed by 19 executives with a total tenure of roughly 169 years, averaging almost 8.0 years of service per executive, having 6.11 employees per reported executive. Evaluation of Psychemedics' management performance can provide insight into the firm performance.
Raymond Kubacki  Chairman
Chairman, CEO and Pres
James Abely  President
Vice President General Counsel
  
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Psychemedics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
For information on how to trade Psychemedics Stock refer to our How to Trade Psychemedics Stock guide.

Psychemedics' Workforce Through the Years

Please note that employee historical analysis has become an increasingly important factor for investors assessing the risk associated with Psychemedics' future performance. Based on our forecasts, it is anticipated that Psychemedics will maintain a workforce of about 130 employees by May 2024.
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid

Psychemedics Management Team Effectiveness

The company has Return on Asset of (0.1176) % which means that on every $100 spent on assets, it lost $0.1176. This is way below average. In the same way, it shows a return on shareholders' equity (ROE) of (0.4763) %, meaning that it generated no profit with money invested by stockholders. Psychemedics' management efficiency ratios could be used to measure how well Psychemedics manages its routine affairs as well as how well it operates its assets and liabilities. The current year's Return On Tangible Assets is expected to grow to -0.3. The current year's Return On Capital Employed is expected to grow to -0.32. At present, Psychemedics' Total Current Assets are projected to increase significantly based on the last few years of reporting. The current year's Non Currrent Assets Other is expected to grow to about 663.6 K, whereas Other Assets are forecasted to decline to about 1.2 M.
As of April 24, 2024, Common Stock Shares Outstanding is expected to decline to about 5.4 M. The current year's Net Loss is expected to grow to about (926.8 K)

Psychemedics Workforce Comparison

Psychemedics is regarded fifth in number of employees category among related companies. The total workforce of Health Care industry is at this time estimated at about 1,949. Psychemedics holds roughly 116 in number of employees claiming about 6% of equities under Health Care industry.
The company has Net Profit Margin of (0.19) %, which means that it does not effectively control expenditures or properly executes on its pricing strategies. This is way below average. In the same way, it shows Net Operating Margin of (0.17) %, which entails that for every $100 of revenue, it lost $0.17.

Psychemedics Insider Trading History

Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Psychemedics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Psychemedics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, Psychemedics insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
 
Oil Shock
 
Dot-com Bubble
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Buy/Sell Ratio# Purchases Trades# Sales TradesTotal Shares PurchasedTotal Shares Sold
2023-09-01
2.25
9
4
 480,000 
 12,700 
2022-12-01
0.25
1
4
 100.00 
 4,500 
2022-06-01
1.8333
11
6
 108,706 
 4,562 
2022-03-01
1.5
3
2
 16,403 
 37.00 
2021-03-01
1.0
2
2
 3,500 
 0.00 
2020-06-01
0.5
1
2
 1,000.00 
 1,399 
2019-12-01
1.0
1
1
 200.00 
 1,000.00 
2019-06-01
1.5714
11
7
 182,550 
 10,961 
2018-12-01
1.0
1
1
 600.00 
 1,400 
2018-06-01
1.25
10
8
 95,746 
 7,698 
2017-12-01
2.0
2
1
 1,200 
 1,000.00 
2017-06-01
0.5333
8
15
 102,500 
 15,519 
2016-12-01
0.0769
1
13
 200.00 
 23,692 
2016-06-01
0.5625
9
16
 112,100 
 11,362 
2016-03-01
9.0
9
1
 9,207 
 1,000.00 
2015-09-01
7.0
7
1
 52,000 
 0.00 
2015-06-01
0.4286
12
28
 146,350 
 231,970 
2014-06-01
1.1667
7
6
 37,375 
 8,771 
2014-03-01
0.4667
7
15
 39,900 
 60,551 
2013-09-01
0.5
1
2
 6,438 
 10,488 
2013-06-01
0.6364
7
11
 47,500 
 11,270 
2013-03-01
0.5
1
2
 5,150 
 9,143 
2012-12-01
0.25
1
4
 470.00 
 3,000 
2012-06-01
1.1429
8
7
 59,000 
 7,378 
2011-06-01
1.3333
8
6
 56,195 
 6,377 
2010-12-01
0.3333
1
3
 1,000.00 
 106,000 
2010-06-01
0.9
9
10
 81,500 
 4,867 
2008-12-01
1.0
2
2
 1,800 
 0.00 
2008-06-01
0.8889
8
9
 30,218 
 10,303 
2007-06-01
1.75
7
4
 34,150 
 6,577 
2007-03-01
0.2857
6
21
 22,600 
 44,700 
2006-06-01
8.0
8
1
 29,050 
 5,150 
2005-06-01
1.8333
11
6
 212,800 
 28,208 
2005-03-01
0.25
3
12
 34,750 
 110,419 
2004-03-01
1.5
3
2
 15,450 
 100,000 
2003-12-01
1.0
2
2
 38,626 
 69,046 
2003-09-01
1.0
1
1
 6,438 
 0.00 

Psychemedics Notable Stakeholders

A Psychemedics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Psychemedics often face trade-offs trying to please all of them. Psychemedics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Psychemedics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
Brian HullingerCEO PresidentProfile
Raymond KubackiChairman, CEO and PresProfile
James AbelyVice President General CounselProfile
Charles DoucotExecutive Vice PresidentProfile
Neil LernerVice President - Finance, TreasurerProfile
Clinton AllenIndependent DirectorProfile
Harry ConnickIndependent DirectorProfile
Fred WeinertIndependent DirectorProfile
Walter TomensonIndependent DirectorProfile
James DykeCorporate VP of Sales and MarketingProfile
Michael SchafferVP of Laboratory OperationsProfile
Charles IVEx VPProfile
Werner BaumgartnerFounderProfile
Annette BaumgartnerFounderProfile
Sarah AshbyVP CounselProfile
Patrick KinneySecretaryProfile
Michael WeisenhoffPrincipal ManagerProfile
Shannon ShoemakerChief OfficerProfile
Daniella MehalikVice FinanceProfile

About Psychemedics Management Performance

The success or failure of an entity such as Psychemedics often depends on how effective the management is. Psychemedics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Psychemedics management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Psychemedics management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Last ReportedProjected for Next Year
Return On Tangible Assets(0.31)(0.30)
Return On Capital Employed(0.34)(0.32)
Return On Assets(0.31)(0.30)
Return On Equity(0.62)(0.59)
The data published in Psychemedics' official financial statements usually reflect Psychemedics' business processes, product offerings, services, and other fundamental events. But there are other numbers, ratios, or fundamental indicators derived from these statements that are easier to understand and visualize within the underlying realities that drive quantitative information of Psychemedics. For example, before you start analyzing numbers published by Psychemedics accountants, it's critical to develop an understanding of what Psychemedics' liquidity, profitability, and earnings quality are in the context of the Health Care Providers & Services space in which it operates.
Please note, the presentation of Psychemedics' financial position, as portrayed in its financial statements, is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Psychemedics' management is honest, while the outside auditors are strict and uncompromising. Whatever the case, the imprecision that can be found in Psychemedics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Psychemedics. Please utilize our Beneish M Score to check the likelihood of Psychemedics' management manipulating its earnings.

Psychemedics Workforce Analysis

Traditionally, organizations such as Psychemedics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Psychemedics within its industry.

Psychemedics Manpower Efficiency

Return on Psychemedics Manpower

Revenue Per Employee190.5K
Revenue Per Executive1.2M
Net Loss Per Employee35.8K
Net Loss Per Executive218.6K
Working Capital Per Employee18.1K
Working Capital Per Executive110.3K
When determining whether Psychemedics is a strong investment it is important to analyze Psychemedics' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Psychemedics' future performance. For an informed investment choice regarding Psychemedics Stock, refer to the following important reports:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Psychemedics. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in population.
For information on how to trade Psychemedics Stock refer to our How to Trade Psychemedics Stock guide.
You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Psychemedics Stock analysis

When running Psychemedics' price analysis, check to measure Psychemedics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Psychemedics is operating at the current time. Most of Psychemedics' value examination focuses on studying past and present price action to predict the probability of Psychemedics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Psychemedics' price. Additionally, you may evaluate how the addition of Psychemedics to your portfolios can decrease your overall portfolio volatility.
Stocks Directory
Find actively traded stocks across global markets
Share Portfolio
Track or share privately all of your investments from the convenience of any device
Idea Analyzer
Analyze all characteristics, volatility and risk-adjusted return of Macroaxis ideas
Competition Analyzer
Analyze and compare many basic indicators for a group of related or unrelated entities
Portfolio Dashboard
Portfolio dashboard that provides centralized access to all your investments
CEOs Directory
Screen CEOs from public companies around the world
Watchlist Optimization
Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm
Is Psychemedics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Psychemedics. If investors know Psychemedics will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Psychemedics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.30)
Dividend Share
0.07
Earnings Share
(0.72)
Revenue Per Share
3.85
Quarterly Revenue Growth
(0.12)
The market value of Psychemedics is measured differently than its book value, which is the value of Psychemedics that is recorded on the company's balance sheet. Investors also form their own opinion of Psychemedics' value that differs from its market value or its book value, called intrinsic value, which is Psychemedics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Psychemedics' market value can be influenced by many factors that don't directly affect Psychemedics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Psychemedics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Psychemedics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Psychemedics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.